The BCR-ABL Variant Panel is a specialized genetic test aimed at detecting specific mutations within the BCR-ABL gene. This gene is most commonly associated with chronic myeloid leukemia (CML) and, to a lesser extent, acute lymphoblastic leukemia (ALL). The test specifically looks for the Mbcr-b2a2 (e13a2), b3a2 (e14a2), and b2a3 variants, which are indicative of the presence of the Philadelphia chromosome, a genetic abnormality found in the majority of CML cases and a portion of ALL cases.

The presence of these mutations is a critical factor in diagnosing these types of leukemia and plays a significant role in determining the most effective treatment plan. Targeted therapies, such as tyrosine kinase inhibitors (TKIs), have been developed to specifically target cells containing the BCR-ABL fusion protein, making the detection of these mutations particularly important for patient care.

The test cost is set at 1800 AED and is conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities. By offering this test, DNA Labs UAE provides essential diagnostic information that can significantly impact the treatment and management of patients with CML and ALL, potentially improving patient outcomes through personalized medicine.